ARRY-382

Cat. No.:	HY-136362
CAS No.:	1313407-95-2
Molecular Formula:	$C_{32}H_{36}N_8O_2$
Molecular Weight:	564.68
Target:	c-Fms
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 8.33 mg/mL (14.75 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.7709 mL	8.8546 mL	17.7091 mL
	5 mM	0.3542 mL	1.7709 mL	3.5418 mL
	10 mM	0.1771 mL	0.8855 mL	1.7709 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 0.83 mg/mL (1.47 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 0.83 mg/mL (1.47 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 0.83 mg/mL (1.47 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

ARRY-382 is a potent, oral and highly selective inhibitor of CSF1R/c-Fms with an IC_{50} of 9 nM. ARRY-382 can be used for the research of advanced or metastatic cancers[1].

IC_{50} & Target

IC50: 9 nM (CSF1R/c-Fms)[1]

In Vitro

ARRY-382 (1 μM) dramatically decreases the number of nurse-like cells (NLCs) compared to untreated cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. David K Edwards V, et al. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget. 2018 May 15;9(37):24576-24589.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA